Cell And Gene Articles, App Notes, Case Studies, & White Papers

  1. Efficient Monitoring Of Escherichia Coli Feeding Strategies 6/10/2026

    Consistent, contamination-free sampling is critical for reliable bioprocess data. Automation enables frequent, hands-free collection, improving efficiency and insight while reducing manual workload.

  2. Effective Strategies To Minimize Product Loss During Fill Finish 5/11/2026

    Every drop of high-value biologic lost in fill finish is money left on the table. Learn practical strategies to protect your yield.

  3. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

    Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

  4. Inside The Payer Perspective On Cell And Gene Therapy Coverage 3/2/2026

    Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.

  5. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

    Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

  6. How Automated ADC Filling Cuts Labor By 90% 5/20/2026

    Manual ADC filling demands 30 labor hours per batch, introduces contamination risk, and leaves product recovery to chance.See how automation cut that to 2 hours with ROI in under a year.

  7. Protect Your Columns And Your Peaks 2/24/2026

    Learn how thoughtful filter selection can protect LC systems, improve protein recovery, and support reliable chromatographic results with key performance data and solvent compatibility insights.

  8. Aseptic Process Design And Simulation Under Annex 1 Guidelines 1/9/2026

    Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.

  9. Risk Assessment Services Align With FDA Guidance For Gene-Edited Human Gene Therapy Products 7/29/2025

    Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.

  10. Synthetic DNA As An Alternative For Scalable Viral Vector Production 3/30/2026

    Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility.